Case Report: Treatment of systemic mastocytosis with sunitinib.

Abstract

Mast cell activation disease typically presents as chronic multisystem polymorbidity of generally inflammatory ± allergic theme.  Presently, treatment of the rare, cytoproliferative variant systemic mastocytosis employs empirically selected therapies to impede mast cell mediator production and action and, when necessary, inhibition of proliferation. Some tyrosine kinase inhibitors (TKIs) have been used successfully in uncommon cases of systemic mastocytosis not bearing that disease's usual imatinib-resistant KIT D816V mutation. Recently, sunitinib, a multi-targeted TKI, had been successful in a case of systemic mast cell activation syndrome. In addition, most allergy is principally a mast cell activation phenomenon, and sunitinib has been shown helpful in controlling a murine model of oral allergy syndrome. Here, we present the first use of sunitinib in systemic mastocytosis.

• Authors: Gerhard J Molderings, Lawrence B Afrin, Hans-Jörg Hertfelder, Stefan Brettner
• Journal: F1000Research (F1000Res) Vol. 6 Pg. 2182 ( 2017) ISSN: 2046-1402 [Print] England
• PMID: 29770197 (Publication Type: Journal Article)